Gastrointestinal adverse events Very common (10% or more): Diarrhea (35%), abdominal pain (21%), vomiting (21%), nausea (12%) Common (1% to 10%): Constipation, dyspepsia, gastrointestinal disorder, melena Very rare (less than 0.01%): Abdominal cramps [Ref] Nervous system Very common (10% or more): Headache (37%), dizziness (18%), paresthesia (12%) Common (1% to 10%): Hypertonia, vertigo, taste perversion Frequency not reported : Seizures (with or without pre-existing seizure activity), increase in seizure frequency and/or severity [Ref] Metabolic Very common (10% or more): Hypercalcemia (15%), hypervolemia (12%) Common (1% to 10%): Anorexia, hyperkalemia [Ref] There are reports from clinical trials of significant hypertriglyceridemia associated with high doses of levocarnitine (3 g/day) given to uremic dialysis patients

The company, which has ties to Marty Makary, President Donald Trumps pick to lead the FDA, also said its working with manufacturers to secure deeper discounts on the medications in late 2025 and into 2026
Because tirzepatide activates GIP receptors in addition to GLP-1 receptors, you get an entirely separate signaling pathway
Scale changes during this phase average two to four pounds for most patients
Setting appropriate expectations during this time can improve adherence and treatment satisfaction